Hematopoiesis News Volume 11.15 | Apr 21 2020

TOP STORY

Adaptive Response to Inflammation Contributes to Sustained Myelopoiesis and Confers a Competitive Advantage in Myelodysplastic Syndrome HSCs

Researchers found that chronic inflammation was a determinant for the competitive advantage of myelodysplastic syndrome (MDS) hematopoietic stem and progenitor cells (HSPCs) and for disease progression. The cell-intrinsic response of MDS HSPCs, which involved signaling through the noncanonical NF-κB pathway, protected these cells from chronic inflammation as compared to normal HSPCs. [Nat Immunol] Abstract

(Ranked by impact factor of the journal)

Overcoming Wnt-β-Catenin Dependent Anticancer Therapy Resistance in Leukemia Stem Cells

Scientists repurposed doxorubicin (DXR) as a targeted inhibitor rather than a broadly cytotoxic chemotherapy. Targeted DXR reduced Akt-activated β-catenin levels in chemoresistant leukemia stem cells (LSCs) and reduced LSC tumorigenic activity. [Nat Cell Biol] Abstract

Extreme Disruption of Heterochromatin Is Required for Accelerated Hematopoietic Aging

The authors used individual and dual deletion of Suv39h1 and Suv39h2 enzymes to examine the causal role of heterochromatin loss in haematopoietic cell development. [Blood] Abstract

Aging-Induced IL27Ra Signaling Impairs Hematopoietic Stem Cells

Investigators showed that aging-related inflammation promoted HSC aging through TNFα→ERK→ETS1→IL27Ra pathway. TNFα, a well-known biomarker of inflammation, increased during aging and induced the expression of IL27Ra on HSCs via ERK-ETS1 signaling. [Blood] Abstract

RUNX1–205, a Novel Splice Variant of the Human RUNX1 Gene, Has Blockage Effect on Mesoderm-Hemogenesis Transition and Promotion Effect during the Late Stage of Hematopoiesis

A human embryonic stem cell line with inducible runt-related transcription factor 1 (RUNX1)-205 overexpression was established. Analyses of these cells revealed that induction of RUNX1-205 overexpression at early stage did not influence the induction of mesoderm but blocked the emergence of CD34⁺ cells, and the production of hematopoietic stem/progenitor cells was significantly reduced. [J Mol Cell Biol] Abstract | Graphical Abstract

Transcriptome Dynamics of Hematopoietic Stem Cell Formation Revealed Using a Combinatorial Runx1 and Ly6a Reporter System

Investigators generated a Tg(Runx1-mKO2; Ly6a-GFP) dual reporter mouse to visualize hematopoietic commitment and studied pre-HSC emergence and maturation. [Stem Cell Reports] Full Article

KLF1/EKLF Expression in Acute Leukemia Is Correlated with Chromosomal Abnormalities

Scientists made the finding that higher KLF1 levels were correlated with cells containing abnormal chromosomes, and that high KLF1 expression was not limited to acute myeloid leukemia associated with erythroid/megakaryoblastic differentiation. [Blood Cells Mol Dis] Abstract

CLINICAL RESEARCH

Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era

Researchers report outcomes of 348 patients with primary plasma cell leukemia receiving autologous hematopoietic cell transplantation (HCT) and allogeneic HCT between 2008 and 2015. [Leukemia] Abstract

Impact of Type of Reduced‐Intensity Conditioning Regimen on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Classical Hodgkin Lymphoma

The authors analyzed 492 adult patients undergoing human leucocyte antigen‐matched sibling or unrelated donor allo‐HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan, fludarabine/melphalan or fludarabine/cyclophosphamide. [Br J Haematol] Abstract

Higher Efficacy of Intermediate Dose Cytarabine + G‐CSF Compared to Cyclophosphamide + G‐CSF in Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma

Since the data regarding Ara‐C in HSC mobilization is limited, scientists compared retrospectively the efficiency and to×icity of G‐CSF combined with either Ara‐C or cyclophosphamide in multiple myeloma patients. [J Clin Apher] Abstract

Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News.

Hematopoiesis and Cardiovascular Disease

Scientists focus on the key cells and products that regulate hematopoiesis under homeostatic conditions, during atherosclerosis and after myocardial infarction. [Circ Res] Abstract

The Nlrp3 Inflammasome as a “Rising Star” in Studies of Normal and Malignant Hematopoiesis

The authors shed more light on an intriguing intracellular protein complex that has become a “rising star” in studies focused on both normal steady-state and pathological hematopoiesis. [Leukemia] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells

Gilead Sciences, Inc., Kite, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on NK cells. [Gilead Sciences, Inc.] Press Release

Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells

Cerus Corporation announced an amendment to the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). [Cerus Corporation] Press Release

Untapped Potential: More US Labs Could Be Providing Tests for Coronavirus

A survey of more than 4,000 researchers in the United States suggests that better coordination at an institutional and national level could make hundreds of thousands more tests for coronavirus available. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Immunology/Molecular Biology (NIH National Heart, Lung, and Blood Institute)

Research Technician – Hematopoietic Stem Cell Biology (Karolinska Institutet)

Postdoctoral Associate – Hematopoiesis (The Jackson Laboratory)

PhD Position – Leukemic Stem Cells and Metabolism (University of Bern)

Postdoctoral Position – Regenerative Medicine (Hannover Medical School)

Research Fellow – Cancer Biology (Dana Farber Cancer Institute)

Scientist – Cancer Immunotherapy (Asgard Therapeutics and Lund University)

Postdoctoral Fellow – Hematopoiesis Research (Harvard Medical School)

Postdoctoral Researcher – Pediatric Oncology (Universitätsklinikum Carl Gustav Carus)

Assistant/Associate Professor – Hematology & Oncology (UC Davis School of Medicine)

Associate/Professor – Hematology & Oncology (UC Davis School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.